Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis

CONCLUSIONS: Given the results suggesting shorter sustainability, the need for earlier intensification and thus higher drug exposure, and the greater need for immunosuppression with infliximab than with adalimumab, the choice of these drugs cannot be considered completely equitable.IMPACT: Our study identified predictors of sustainability of biologic treatment in paediatric patients with Crohn's disease, including adalimumab (versus infliximab), early initiation of biologic treatment, and normalised baseline haemoglobin levels. Infliximab treatment was associated with earlier intensification, higher drug exposure, and a greater need for immunosuppression. Parents and patients should be fully informed of the disadvantages of intravenous infliximab versus adalimumab during the decision-making process. This study emphasises the importance of not delaying the initiation of biologic therapy in paediatric patients with Crohn's disease.PMID:38012309 | DOI:10.1038/s41390-023-02913-7

Source: Pediatric Research - November 27, 2023 Category: Pediatrics Authors: Ondrej Hradsky Ivana Copova Marianna Durilova Denis Kazeka Tereza Lerchova Katarina Mitrova Jan Schwarz Romana Vetrovcova Nabil El-Lababidi Eva Karaskova Maria Veghova-Velganova Astrid Sulakova Lucie Gonsor číková Marketa Veverkova Ivana Zeniskova Mart Source Type: research